vs

Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and Sanofi (SNY). Click either name above to swap in a different company.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AARD
AARD
SNY
SNY
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Net Profit
AARD
AARD
SNY
SNY
Q4 25
$-17.6M
Q3 25
$-16.3M
Q2 25
$-14.4M
Q1 25
$-9.3M
EPS (diluted)
AARD
AARD
SNY
SNY
Q4 25
$-0.81
Q3 25
$-0.75
Q2 25
$-0.66
Q1 25
$-0.71

Related Comparisons